| Literature DB >> 35287599 |
Fei Zhang1,2,3, Jinbiao Zhong1,2,3, Handong Ding1,2,3, Guiyi Liao4,5,6.
Abstract
BACKGROUND: Infections remain a major cause of morbidity and mortality in kidney transplant (KT) recipients. This study aimed to investigate the preservation fluid (PF) samples from deceased donors and report the impacts of possible donor-derived carbapenem-resistant Klebsiella pneumoniae (pdd-CRKP) infections on KT recipients.Entities:
Keywords: Carbapenem-resistant Klebsiella pneumoniae; Donor-derived infection; Kidney transplantation; Possible donor-derived carbapenem-resistant Klebsiella pneumoniae; Preservation fluid
Mesh:
Substances:
Year: 2022 PMID: 35287599 PMCID: PMC8919621 DOI: 10.1186/s12882-022-02733-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline characteristics of donors with or without a CRKP-positive preservation fluid culture
| Characteristics | Donors with CRKP-positive PF | Donors without CRKP-positive PF | |
|---|---|---|---|
| Sex, male n (%) | 7(63.6) | 51(54.8) | 0.751 |
| Age (years) | 50.82 ± 9.19 | 48.57 ± 9.93 | 0.476 |
| Brain trauma | 6(54.5) | 51(54.8) | 0.985 |
| Cerebrovascular accidents | 3(27.3) | 19(20.4) | 0.696 |
| Brain tumour | 1(9.1) | 11(11.8) | 0.788 |
| Others | 1(9.1) | 12(12.9) | 0.718 |
| I | 1(9.1) | 17(18.3) | 0.685 |
| II | 1(9.1) | 21(22.6) | 0.450 |
| III | 9(81.8) | 55(59.1) | 0.197 |
| ICU stay in days, median (IQR) | 30(21-39) | 11(9-14) | P<0.001 |
| Warm ischaemia time (min), median (IQR) | 11(10-13) | 11(9-14) | 0.928 |
Baseline characteristics of recipients with a CRKP-positive preservation fluid culture
| Characteristics | Recipients with graft loss or death | Recipients without graft loss or death | |
|---|---|---|---|
| Sex, male n (%) | 5(83.3) | 10(71.4) | 0.573 |
| Age (years) | 36.8 ± 8.9 | 36.0 ± 11.8 | 0.879 |
| BMI (kg/m2) | 22.5 ± 3.8 | 22.4 ± 3.6 | 0.948 |
| HTA | 1(16.7) | 1(7.1) | 0.521 |
| DM | 1(16.7) | 1(7.1) | 0.521 |
| Glomerulonephritis | 4(66.7) | 11(78.6) | 0.613 |
| Others | 0(0.0) | 1(7.1) | 0.502 |
| HD | 4(66.7) | 12(85.7) | 0.549 |
| PD | 2(33.3) | 2(14.3) | 0.549 |
| Duration of HD | 1.5(0.0-5.5) | 2.0(0.4-5.0) | 0.588 |
| Duration of PD | 0.0(0.0-1.8) | 0.0(0.0-0.0) | 0.345 |
| DGF n (%) | 1(16.7) | 5(35.7) | 0.613 |
| ATG induction n (%) | 2(33.3) | 5(35.7) | 0.919 |
| Pdd-CRKP infection (%) | 6(100.0) | 9(64.3) | 0.091 |
| Antibiotic regimen containing ceftazidime avibatan (%) | 1(16.7) | 11(78.6) | 0.018 |
Abbreviations: BMI body mass index, HTA hypertension, DM diabetes mellitus, HD haemodialysis, PD peritoneal dialysis, DGF delayed graft function, ATG anti-thymocyte globulin
Frequency and incidence of infection in recipients with a CRKP-positive preservation fluid culture
| Infectious events | Number of cases (n) | Incidence ( |
|---|---|---|
| Surgical site infection | 11 | 55.0% |
| Infectious allograft kidney artery disruption | 1 | 5.0% |
| Urinary tract infection | 3 | 15.0% |
| pneumonia | 2 | 10.0% |
| Bloodstream infection | 10 | 50.0% |
Prophylactic antimicrobial therapy regimens in recipients with a CRKP-positive preservation fluid culture
| Prophylactic antimicrobial therapy regimens(n) | Death(n) | Graft loss(n) | Patient and graft survival(n) |
|---|---|---|---|
| Tigecycline+ imipenem / meropenem (8/20) | 3 | 2 | 3 |
| CAZ-AVI + meropenem (5/20) | 0 | 0 | 5 |
| CAZ-AVI as initial therapy (4/20) | 0 | 0 | 4 |
| CAZ-AVI as salvage therapy (3/20) | 0 | 1 | 2 |
Abbreviations: CAZ-AVI Ceftazidime-Avibatan
Antimicrobial susceptibility of isolates from recipients with pdd-CRKP infections
| Antibiotic | Susceptible (%) |
|---|---|
| Ceftazidime | 0.0 |
| Levofloxacin | 13.3 |
| Gentamycin | 20.0 |
| Imipenem | 0.0 |
| Meropenem | 0.0 |
| Amikacin | 40.0 |
| Polymyxin | 86.7 |
| Tigecycline | 93.3 |
| Ceftazidime-Avibatam | 100.0 |